# FMC-376

Source: https://onco.cc/drugs/fmc-376/  
OnCo record `fmc-376` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FMC-376 is an experimental oral covalent small molecule from Frontier Medicines, in phase 1 trials for KRAS G12C-mutated solid tumours and non-small cell lung cancer.

## Summary

FMC-376 is an oral covalent small molecule from Frontier Medicines. A dual inhibitor that targets both the active (GTP-bound, 'ON') and inactive (GDP-bound, 'OFF') forms of KRAS G12C. Its furthest stage is phase 1, for KRAS G12C-mutated solid tumours and non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 PROSPER NCT06244771 recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: FMC-376
- Modality: Oral covalent small molecule
- Mechanism: A dual inhibitor that targets both the active (GTP-bound, 'ON') and inactive (GDP-bound, 'OFF') forms of KRAS G12C.

## Sources

- Frontier Medicines: frontiermeds.com: https://www.frontiermeds.com/precision-pipeline/KRAS-GTP
- Frontier Medicines: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06244771
- ClinicalTrials.gov: trials of FMC-376: https://clinicaltrials.gov/search?intr=FMC-376

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Frontier Medicines](https://onco.cc/companies/frontier-medicines/)
- trials: [A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors](https://onco.cc/trials/nct06244771/)

---
JSON: https://onco.cc/api/v1/entities/fmc-376.json